8-K

               SECURITIES AND EXCHANGE COMMISSION
                    Washington, D.C.  20549





                            FORM 8-K




                         CURRENT REPORT
               Pursuant to Section 13 or 15(d) of
              The Securities Exchange Act of 1934


               Date of Report:  February 17, 2005
               (Date of earliest event reported)


                   BIO-RAD LABORATORIES, INC.
  ________________________________________________________________
     (exact name of registrant as specified in its charter)


                       Commission File: 1-7928

      Delaware                                  94-1381833
  ________________________________________________________________
    (State or other                         (I.R.S. Employer
    jurisdiction of                        Identification No.)
   incorporation or
     organization)



                     1000 Alfred Nobel Dr.
                   Hercules, California 94547
  ________________________________________________________________
    (Address of Principal executive offices, including zip code)

                         (510) 724-7000
  ________________________________________________________________
      (Registrant's telephone number, including area code)



  





  ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

       The information in Item 2.02 of this Report, including Exhibit 99.1
  attached hereto, is being furnished pursuant to Item 2.02 of Form 8-K.
  Consequently, it is not deemed "filed" for the purposes of Section 18 of
  the Securities and Exchange Act of 1934, as amended, or otherwise subject
  to the liabilities of that section. It may only be incorporated by
  reference in another filing under the Exchange Act or Securities Act of
  1933, as amended, if such subsequent filing specifically references this
  Form 8-K.

       On February 17, 2005, Bio-Rad Laboratories, Inc. announced its results
  of operations and financial condition as of and for the fourth quarter ended
  December 31, 2004.  A copy of the press release is attached hereto as
  Exhibit 99.1 and is incorporated herein by reference.






  ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS.


       (c)  Exhibits

  Exhibit
  Number                            Description

  99.1   Press Release for fourth quarter financial results of Bio-Rad
         Laboratories, Inc., dated February 17,2005. This exhibit
         is being furnished pursuant to Item 2.02 of Form 8-K.








   

                                 SIGNATURES



       Pursuant to the requirements of the Securities Exchange Act of 1934,
  the Registrant has duly caused this report to be signed on its behalf by
  the undersigned hereunto duly authorized.


                                        BIO-RAD LABORATORIES,INC.



  Date:  February 17, 2005              By: /s/ Christine A. Tsingos
                                            Christine A. Tsingos
                                            Chief Financial Officer


  


                              EXHIBIT INDEX

  Exhibit
  Number                       Description


  99.1   Press Release for fourth quarter financial results of Bio-Rad
         Laboratories, Inc., dated February 17, 2004.  This exhibit
         is being furnished pursuant to Item 2.02 of Form 8-K.

EX-99

FOR IMMEDIATE RELEASE

Bio-Rad Laboratories Reports Fourth-Quarter and Full-Year Financial Results

HERCULES, CA – February 17, 2005 – Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced financial results today for the fourth quarter ended December 31, 2004.  Fourth-quarter netsales from continuing operations were $307.9 million, up 19.3 percent compared to the $258.1 million reported for the same quarter of 2003.  On a currency-neutral basis, revenues were up 14.1 percent versus fourth-quarter 2003 results.  This growth was largely due to a combination of events including organic growth in Bio-Rad’s two main business segments and the addition of MJ GeneWorks products to the Company’s portfolio.  For the quarter, income from continuing operations was $17.1 million compared to $18.6 million in the fourth quarter of last year.

For the full year, overall Company sales from continuing operations grew by 11.3 percent to $1,090.0 million compared to $979.6 million in 2003.  Normalizing for the impact of currency effects, growth was 5.5 percent.  Year-over-year income from continuing operations fell by 14.2 percent to $66.3 million, or $2.58 per share, from $77.3 million, or $3.04 per share in 2003, due to the Company’s acquisition and integration of MJ GeneWorks which included more than $14 million of one-time costs, continued investment in R&D and infrastructure development projects, and additional expenses associated with Sarbanes-Oxley Act compliance.  Full-year gross margin from continuing operations was 56.0 percent, down slightly compared to 56.8 percent over the same period of 2003.

Fourth-Quarter Highlights

·

Overall net sales from continuing operations for the fourth quarter grew by 19.3 percent versus fourth-quarter 2003 results.

·

Fourth-quarter basic earnings from continuing operations were $0.66 per share, or $0.65 per share on a diluted basis, compared to $0.73 and $0.71, respectively, in the same period of last year.

·

Segment net sales for the quarter were 21.6 percent higher for the Life Science segment and 17.1 percent higher for the Clinical Diagnostics segment compared to their respective figures in 2003.

·

During the quarter, Bio-Rad sold $200 million aggregate principal amount of 6.125% Senior Subordinated Notes due 2014 in a private offering.

Life Science segment net sales for the quarter were $148.5 million, 21.6 percent higher than last year’s comparable period.  On a currency-neutral basis, segment sales grew by 16.4 percent.  Full-year reported sales from continuing operations were $504.7 million for the segment, up 10.6 percent over the previous year, or 4.8 percent on a currency-neutral basis.  Performance in this segment was boosted by the addition of acquired MJ GeneWorks products and by increased sales in several product areas including multiplex array technology and

amplification reagents.  During the quarter, the Life Science Group launched a number of products including the new Experion^TM Automated Electrophoresis System, a novel approach to RNA and protein analysis and separation that will revolutionize the way electrophoresis is performed.  The Life Science segment was negatively impacted by price erosion in the BSE (bovine spongiform encephalopathy or mad cow disease) product line, which was partially offset by a continued expansion in unit volume.

The Clinical Diagnostics segment reported net sales of $156.7 million for the quarter, up 17.1 percent compared to the fourth quarter of 2003, or 11.9 percent excluding currency effects.  Full-year segment sales from continuing operations were $576.4 million, a 12.0 percent increase compared to 2003 results, or 6.3 percent excluding currency effects.  These results are due in part to continued growth in the blood virus, diabetes monitoring and quality controls product lines.  During the quarter, the Company received marketing clearance from the U.S. Food and Drug Administration (FDA) for its new BioPlex™2200 system, a revolutionary new immunoassay platform that employs multiplexing technology to analyze for multiple disease states from single patient samples.  Bio-Rad also received approval from the FDA for its new Multispot HIV-1/HIV-2 Rapid Test, the only single-use assay to be approved by the FDA for the d etection and differentiation of HIV-1 and HIV-2 antibodies.  Also during the quarter, the Clinical Diagnostics Group won a major blood-bank tender in Russia, making Bio-Rad the largest supplier of HIV and hepatitis blood screening products in that country.

2004 Highlights

·

Full-year Company sales from continuing operations grew by 11.3 percent to $1,090.0 million.

·

Year-over-year income from continuing operations fell by 14.2 percent to $66.3 million from $77.3 million in 2003.

·

In March, the Company purchased the assets of Hematronix Inc. for approximately $17 million in cash.  This acquisition further enhances Bio-Rad’s leadership position in the quality-control management industry.

·

In August, the Company purchased MJ GeneWorks, Inc. and its subsidiaries, including MJ Research, Inc., for approximately $31 million in cash and the assumption of certain liabilities of those companies.  The acquisition significantly enhances Bio-Rad’s portfolio of gene expression products.

“2004 was as much a year of investment as it was of continued progress.  The year brought increased organic growth in our core businesses, expansion of our product lines through new product introductions and strategic acquisitions, infrastructure improvements and increased R&D,” said Norman Schwartz, President and Chief Executive Officer.  “These efforts give Bio-Rad a larger proprietary-technology base, improved operational systems and an increased presence in certain key markets, all of which help strengthen the foundation for future success.”

Management will discuss these results in a conference call at 2:00 p.m. PT (5:00 p.m. ET) February 17, 2005. Interested parties can access the call by dialing (800) 901-5217 (in the U.S.), or (617) 786-2964 (international), access number 43140553.  The live web cast can be accessed at http://www.bio-rad.com.  A replay of the call will be available at (888) 286-8010 (in the U.S.), or (617) 801-6888 (international), access number 58162472, for seven days following the call and the web cast can be accessed at http://www.bio-rad.com for 30 days.

Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research products and clinical diagnostics.  It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.

Various statements made within this press release may constitute “forward-looking statements” for purposes of the Securities and Exchange Commission’s “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934.

The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company’s expectations.

For more information contact:

Christine Tsingos, Vice President and Chief Financial Officer, or

Ron Hutton, Treasurer

Bio-Rad Laboratories, Inc.

Phone:  (510) 724-7000

E-mail:  investor_relations@bio-rad.com

Bio-Rad Laboratories, Inc.
Fourth-Quarter and Full-Year 2004
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(UNAUDITED)
		Three Months, Ended December 31,		Twelve Months, Ended December 31,
		2004	2003	2004	2003
Net sales		$307,868	$258,098	$1,090,012	$979,631
Cost of goods sold		139,533	112,598	479,939	423,401
Gross profit		168,335	145,500	610,073	556,230
Selling, general and administrative expense		110,825	87,037	378,264	317,524
Product research and development expense		31,885	25,648	108,344	91,273
Purchased in-process research and development expense		-	-	14,620	-
Interest expense		5,255	4,772	20,219	31,006
Foreign exchange losses		774	1,242	2,394	4,080
Other income, net		(7,789)	(1,001)	(11,095)	(3,012)
Income from continuing operations before taxes		27,385	27,802	97,327	115,359
Provision for income taxes		10,274	9,164	31,035	38,055
Income from continuing operations		17,111	18,638	66,292	77,304
Discontinued operations
	Gain (loss) from discontinued operations, net of tax	-	553	(1,487)	(1,133)
	Gain on divestiture, net of tax	-	-	3,437	-
	Total discontinued operations	-	553	1,950	(1,133)
Net income		$  17,111	$  19,191	$     68,242	$  76,171
Basic earnings per share
	Continuing operations	$     0.66	$     0.73	$        2.58	$     3.04
	Discontinued operations	-	0.02	0.07	(0.04)
	Net income	$     0.66	$     0.75	$        2.65	$     3.00
	Weighted average common shares	25,819	25,524	25,724	25,416
Diluted earnings per share
	Continuing operations	$     0.65	$     0.71	$        2.50	$     2.94
	Discontinued operations	-	0.02	0.08	(0.04)
	Net income	$     0.65	$     0.73	$        2.58	$     2.90
	Weighted average shares	26,528	26,405	26,489	26,310
Certain items have been reclassified to conform to the current year presentation.

Bio-Rad Laboratories, Inc.
Summary Condensed Consolidated Balance Sheets
(In thousands, except per share data)
(UNAUDITED)
			At December 31,	At December 31,
			2004	2003
Current Assets:
	Cash and cash equivalents		$              195,734	$                65,395
	Short-term investments		165,899	83,247
	Accounts receivable, net		261,243	234,085
	Inventories, net		205,512	190,258
	Deferred tax assets		34,492	31,056
	Prepaid expenses and other current assets		48,344	51,357
		Total current assets	911,224	655,398
Property, plant and equipment, net			202,324	179,123
Goodwill, net			113,276	69,503
Purchased intangibles, net			58,638	12,251
Long-term tax assets			26,544	21,218
Other assets			79,996	55,103
		Total assets	$           1,392,002	$              992,596
Current liabilities:
	Notes payable and current maturities of long-term debt		$                  9,457	$                10,423
	Accounts payable		71,194	53,995
	Accrued payroll and employee benefits		79,061	71,650
	Sales, income and other taxes payable		15,835	20,833
	Litigation accrual		50,000	-
	Accrued royalties		39,317	34,168
	Other current liabilities		50,511	48,183
		Total current liabilities	315,375	239,252
Long-term debt, net of current maturities			425,979	225,835
Deferred tax liabilities			24,772	14,803
Other long-term liabilities			28,988	16,899
Stockholder's equity			596,888	495,807
		Total liabilities and stockholder's equity	$           1,392,002	$              992,596
Certain items have been reclassified to conform to the current year presentation.

Bio-Rad Laboratories, Inc.
Summary Condensed Consolidated Statement of Cash Flows
(In thousands, except per share data)
(UNAUDITED)
		Twelve Months Ended
		2004	2003
Cash flows from operating activities:
	Cash received from customers	$    1,081,645	$   996,384
	Cash paid to suppliers and employees	(912,286)	(800,633)
	Interest paid	(19,543)	(17,088)
	Income tax payments	(33,637)	(51,280)
	Miscellaneous receipts	8,933	1,928
	Discontinued operations	(2,019)	(1,671)
	Net cash provided by operating activities	123,093	127,640
Cash flows from investing activities:
	Capital expenditures, net	(60,493)	(69,003)
	Other investing activities	(125,825)	(121,238)
	Net cash used in investing activities	(186,318)	(190,241)
Cash flows from financing activities:
	Long-term borrowings	200,000	249,335
	Payments on long-term debt	(1,781)	(132,012)
	Other financing activities	(4,992)	(9,154)
	Net cash provided by financing activities	193,227	108,169
Effect of exchange rate changes on cash		337	(7,906)
Net increase in cash and cash equivalents		130,339	37,662
Cash and cash equivalents at beginning of period		65,395	27,733
Cash and cash equivalents at end of period		$       195,734	$     65,395
Reconciliation of income from continuing operations to net cash provided by operating activities:
Income from continuing operations		$         66,292	$     77,304
Adjustments to reconcile net income to net cash provided by operating activities (net of effects of acquisitions):
	Depreciation and amortization	56,143	42,009
	Changes in working capital and other	2,145	9,460
	Discontinued operations	(1,487)	(1,133)
Net cash provided by operating activities		$       123,093	$   127,640
Certain items have been reclassified to conform to the current year presentation.